Introduction: Autophagy not only plays an important role in the progression of cancer but is also involved in tissue inflammatory response. However, few published studies have investigated associations between functional genetic variants of autophagy-related genes and radiation pneumonitis (RP) as well as clinical outcomes in patients with NSCLC after definitive radiotherapy.
Introduction
Lung cancer ranks at the top for cancer-related mortality, with more than a million deaths each year worldwide. 1 In the United States, there were approximately 222,500 new cases and 155,870 deaths in 2017. 2 NSCLC is the most common histological type, accounting for approximately 90% of all patients with lung cancer. median survival remains less than a year, and the 2-year survival rate is still 15% to 20%. 4 Moreover, radiation pneumonitis (RP), which can occur after radiotherapy as a result of inflammation of normal lung tissues injured by radiation, has been identified as one of the most common dose-limiting complications of thoracic radiation. Among treated patients, approximately 10% to 20% have experienced severe RP (i.e., grade !3), almost half of whom died of this radiation complication. 5 Therefore, the discovery of suitable biomarkers is needed to predict RP and outcomes of NSCLC after definitive radiotherapy. Increasing evidence suggests that molecular and genetic factors may play an important role in RP development and subsequent clinical outcomes of NSCLC and are accessible molecular markers that may provide therapeutic benefits by predicting clinical outcomes of the patients with NSCLC on an individual basis. [6] [7] [8] Recently, accumulating evidence has indicated that autophagy plays an important role in various stages of cancer development and progression, including in NSCLC. 9, 10 Autophagy is a catabolic process that degrades intracellular components through the lysosomal machinery, 11 which usually functions at a low level but is upregulated in response to nutrient starvation, stress, or DNA damage. The role of autophagy in cancer development and progression is complex, because it can act as either a tumor suppressor by degradation of damaged proteins and organelles or as a growth promoter by a mechanism of cell survival depending on many factors like tissue type or tumor stage. 12, 13 Generally, autophagy plays an important anticarcinogenic role at an early stage of carcinogenesis by clearing damaged mitochondria and aberrant protein aggregates that produce ROS. Autophagy-related genes (ATGs) play a key role in controlling autophagic formation, and the downregulation of ATG genes directly or indirectly accelerates cancer development and progression. 14 The ATG family in yeast contains 35 15, 16 Studies have demonstrated that some frameshift mutations in ATG genes may have lead to premature cessation of amino acid synthesis of the affected proteins and thus may have inactivated their autophagy function. 17 For example, a mutation in ATG2B caused the loss of 1039 of the total 2078 amino acids, whereas a mutation in ATG5 led to the loss of 41 of the total 275 amino acids. 17 Furthermore, a deficient ATG5 in neural cells led to progressive neurodegeneration, accompanied by the accumulation of cytoplasmic inclusion bodies. 18 Although the exact roles of ATG10, ATG12, and ATG16 are not yet clear, an increased expression of ATG10 was reported to be significantly associated with lymph node metastasis and lymphovascular invasion in colorectal cancer, 19 and overexpression of ATG12 and ATG16 was demonstrated to inhibit autophagosome formation. 20 More recently, ATG12 silencing was shown to significantly reduce breast cancer cell growth in nude mice, which suggests that ATG12 may be an oncogenic protein. 21 Recent clinical studies suggested that cancer radiotherapy induced autophagy directly or indirectly through DNA damage. 22 There are two primary opposing functions of radiation-induced autophagy: cytoprotective and cytotoxic. Although radiation-induced autophagy often serves a protective function in cell culture-based studies, the extent to which autophagy may be induced by radiation in human cancer cells is still unclear, although the reported functions of autophagy in response to radiation are inconsistent. 23 Some studies reported that autophagy promoted the anticancer effects of radiotherapy, 24 whereas others showed that upregulation of autophagy was associated with tumor resistance in radiation therapy and that blockade of autophagy contributed to the radiosensitization. 24 More recent reports suggested that inhibition of autophagy led to an increased expression of interleukin-1B and interleukin-6 and that autophagy played an important role in tissue inflammatory response. 25, 26 However, the role of genetic variants of ATG genes in RP and outcomes of patients with NSCLC after radiotherapy is largely unknown.
To date, only two studies have reported that mRNA expression and genetic variants of ATG genes contributed to survival and brain metastasis in patients with NSCLC in Chinese populations, 8, 27 but none of the published studies investigated functional genetic variants of ATG genes in association with RP and outcomes of patients with NSCLC in a North American population. Potentially functional genetic variants of autophagy genes may alter the host autophagic capacity and thus influence efficiency of therapies. 28 Inspired by these findings, we conducted the present study to test the hypothesis that potentially functional genetic variants in ATG genes are prognostic and predictive for radiationinduced pneumonitis and clinical outcomes in patients with NSCLC after definitive radiotherapy. In the present study, we evaluated the effects of nine functional variants in important ATG genes (e.g., ATGB2, ATG10, ATG12, and ATG16L2) on clinical outcomes among 393 patients with NSCLC in a North American population.
Materials and Methods

Study Populations
Characteristic details of the study population used in the present study were described previously. 7 Briefly, the subjects included 474 patients with primary NSCLC who had been treated with definitive radiation and had available DNA samples as well as clinical follow-up data at a single institution between March 1998 and June 2009. Patients with an inoperable stage I to III disease and patients with oligometastatic stage IV disease (with solitary metastases to the bone or brain) were included. The final group analyzed for single-nucleotide polymorphisms (SNPs) and clinical outcomes consisted of 393 patients who received definitive radiotherapy in the initial treatment, some of whom also received chemotherapy either concurrent with or subsequent to the radiotherapy. Radiation toxicity events were scored according to the Common Terminology Criteria for Adverse Events v3.0, and the details on methods for evaluating local recurrence-free survival (LRFS), progression-free survival (PFS), OS, and RP were also described elsewhere. 7 Briefly, we used computed tomography (CT) with or without positron emission tomography to evaluate RP at each follow-up visit. The time to RP development was calculated from the start of radiation therapy; patients not experiencing either end point were censored at the date of the last follow-up or death. For monitoring recurrence and scan interval, two primary surveillance strategies were used. The first was the chest CT scan at each of the surveillance visits every 3 to 6 months for the first 5 years and annually thereafter. The second was alternating positron emission tomography/CT and CT scans for 1 to 2 years, reserving positron emission tomography/CT for abnormal findings on the CT scan. 29 We also interviewed each of the 393 eligible patients to obtain data on tobacco smoking. Those who had smoked fewer than 100 cigarettes in their lifetime were considered never-smokers, and all others were considered ever-smokers. Techniques for treatment planning and delivery changed considerably during the study period. For example, the three-dimensional CT-based simulation and three-dimensional conformal radiation therapy were used before July 2004, but the four-dimensional CT-based simulation with respiratory motion management and intensity-modulated radiation therapy or proton beam radiation was used thereafter. The University of Texas M. D. Anderson Cancer Center institutional review board approved the present study, and the Health Insurance Portability and Accountability Act regulations were strictly followed.
Selection of SNPs and Genotyping Assays
The selection of candidate genes ATGB2, (3) not in high linkage disequilibrium (i.e., linkage disequilibrium !0.8). As a result, nine functional SNPs in the ATG2B, ATG10, ATG12, and ATG16L2 genes were selected: ATG2B rs17784271 A>G (3 0 UTR) and rs4900321 A>T (3 0 UTR); ATG10 rs10514231 C>T (intron 2), rs6884232 A>G (3 0 UTR), and rs4703533 C>G (the promoter region); ATG12 rs26538 C>T (the promoter region) and rs1058600 C>T (3 0 UTR); and ATG16L2 rs1126205 G>T (the promoter region) and rs10898880 A>C (the promoter region) (Supplementary Table 1) .
We extracted genomic DNA from the buffy coat fraction of the whole blood samples by using a blood DNA mini kit (Qiagen, Valencia, CA) in a process according to the manufacturer's instructions. The DNA purity and concentration were determined by spectrophotometer measurement of absorbance at 260 and 280 nm. The genotyping was performed by using the TaqMan methodology in 384-well plates and read with the Sequence Detection Software on an ABI-Prism 7900 instrument according to the manufacturer's instructions (Applied Biosystems, Foster City, CA). Primers and probes were supplied by Applied Biosystems. Each plate included four negative controls (no DNA), duplicated positive controls, and eight repeat samples. Amplification was done under the following conditions: 50ºC for 2 minutes, 95ºC for 10 minutes, and 60ºC for 1 minute for 40 cycles. The success rate of all the SNP assays was higher than 99%, and the repeated samples' results were 100% concordant.
Bioinformatic Analysis
Differential expression analysis was performed to evaluate the mRNA expression of ATG16L2 in lung squamous carcinoma (LUSC), lung adenocarcinoma (LUAD), and paired adjacent normal tissues by using data generated by The Cancer Genome Atlas. 38 The Encyclopedia of DNA Elements (ENCODE) (https://genome.ucsc.edu/) was used to identify the regulatory potential of the region adjoining the SNP. We assessed the associations between SNPs and mRNA expression levels of ATG16L2 by expression quantitative trait loci analysis by using the data on 338 whole blood cells of individuals of European descendants from the Genotype-Tissue Expression project (https://www.gtexportal.org/home/).
Statistical Analysis
We estimated the associations of the genotypes with RP and clinical outcomes in the patients by using a Cox proportional hazard regression model, with the time to event as described previously. 7 The Kaplan-Meier method was used to visualize RP, LRFS, PFS, and OS by genotype. RP intervals were calculated from the date on which treatment began to the time of incidence of severe RP (grade !3), LRFS intervals were calculated from the date on which treatment began to the time of tumor recurrence or death (i.e., LRFS) or the time of progression or death (i.e., PFS), and the patients were censored at the time of the final follow-up. 39 The OS interval was calculated from the date of diagnosis until death or the date of last contact. Multivariable Cox proportional hazard regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) of each genotype to estimate its effect on RP, LRFS, PFS, and OS with adjustment for confounding factors. Such factors were identified with stepwise Cox regression models that were used to estimate independent predictors of NSCLC prognosis, with a significance level of 0.050 for entering and 0.051 for removing the respective explanatory variables. Further stratified analysis was applied to assess stratified groups. All statistical tests were two sided with a p value of 0.05 considered significant, and all analyses were performed using SAS software version 9.2 (SAS Institute, Cary, NC). We also calculated the false-positive report probability (FPRP) to detect the falsepositive association findings. 40 For all the significant results, we calculated FPRP with prior probabilities of 0.0001, 0.001, 0.01, 0.1, and 0.25. The HR was set close to 0.67 (protection) or 1.50 (risk), and a FPRP value less than 0.2 was considered noteworthy.
Results
Characteristics of the Study Population
Demographic and clinical characteristics of the 393 patients treated with definitive radiotherapy, with or without concurrent or subsequent chemotherapy, are presented in Table 1 Table 1 ).
Associations of SNPs in ATG2B, ATG10, ATG12, and ATG16L2 with LRFS, PFS, OS, and Risk of RP Table 2 and Supplementary Table 2 show genotype distributions of the nine SNPs, the results from the multivariable Cox regression analyses of the associations of the nine SNPs with severe RP, LRFS, and PFS as well as with OS in the patients with NSCLC. As shown in Table 2 , in the multivariable Cox regression analyses, we found that the ATG16L2 rs10898880 variant CC homozygotes had a better LRFS, PFS, and OS (adjusted HR [adjHR] ¼ 0.54, 0.57, and 0.59; 95% CI: 0.39-0.76, 0.41-0.79, and 0.41-0.83; p ¼ 0.0005, 0.0009, and 0.003; p trend test ¼ 0.0004, 0.0007, and 0.002, respectively) than did patients with the AA genotype; and these effects in a recessive genetic model also remained statistically significant for a better LRFS, PFS, and OS (adjHR ¼ 0.59, 0.64, and 0.64; 95% CI: 0.45-0.79, 0.48-0.84, and 0.48-0.86; p ¼ 0.0004, 0.002, and 0.003, respectively) after adjustment for potential confounders, including age, sex, histological grade, MLD, disease stage, KPS score, and GTV (see Table 2 and Fig. 1A-C) . In contrast, we found that patients with the variant Table 2 and Fig. 1D Table 2 ). For the other five SNPs, we did not find any significant association with RP, LRFS, PFS, or OS under either additive or recessive genetic models (see Supplementary Table 2 ). Furthermore, we also performed association analyses for each of the nine SNPs with RP, LFS, PFS, and OS in the presence of the other eight SNPs and significant clinical variables. As shown in Supplementary Table 3 , only the ATG16L2 rs10898880 showed a significant association with clinical outcomes, with two other SNPs (ATG2B rs17784271 and ATG10 rs4703533) showing a significant association with RP. Finally, we calculated the correlation coefficients among SNPs. As shown in Supplementary Table 4 , except for rs1058600, each SNP showed a significant correlation only with those in the same gene (rs17784271 and rs4900321 in ATG2B; rs10514231, rs6884232, and rs4703533 in ATG10; rs26538 and rs1058600 in ATG12; and rs10898880 and rs1126205 in ATG16L2), and rs1058600 also showed a significant correlation with rs4900321, rs6884232, and rs4703533.
Stratified Analyses by Selected Variables
We then performed stratified analyses to evaluate the effects of variant genotypes of ATG16L2 rs10898880 and ATG10 rs4703533 on LRFS, PFS, and OS by age, sex, KPS, RP, radiation pneumonitis; LRFS, local recurrence free survival; PFS, progression-free survival; OS, overall survival; 0, the absence of events; 1, the presence of events; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; MLD, mean lung dose; IMRT, intensity-modulated radiation therapy; 3DCRT, three-dimensional conformal radiotherapy; ORT, overall radiation time; GTV, gross tumor volume. Table 6 ).
Because most of the significant findings were in the subgroup analyses, we calculated the FPRP values for all nine of the SNPs (Supplementary Table 7 ) and all the observed significant associations. As shown in Table 4 , 3 . RP, radiation pneumonitis; LRFS, local recurrence-free survival; PFS, progression-free survival; OS, overall survival; 0, the absence of events; 1, the presence of events; HR, hazard ratio; CI, confidence interval; KPS, Karnofsky performance status; MLD, mean lung dose; GTV, gross tumor volume.
when the assumption of a prior probability was 0.25, the associations of severe RP and clinical outcomes with the ATG16L2 rs10898880CC genotype (a recessive genetic model) were still noteworthy for all subjects (FPRP ¼ 0.144, 0.001, 0.004, and 0.010 for RP, LRFS, PFS, and OS, respectively), those younger than 65 years (FPRP ¼ 0.154, 0.010, 0.015, and 0.099 for RP, LRFS, PFS, and OS, respectively), and those with stage III or IV disease (FPRP ¼ 0.166, 0.002, 0.006, and 0.016 for RP, LRFS, PFS, and OS, respectively). When the assumption of a prior probability was 0.1, the associations of clinical outcomes with the ATG16L2 rs10898880CC genotype (a recessive genetic model) were still noteworthy for all subjects (FPRP ¼ 0.004, 0.012, and 0.028 for LRFS, PFS, and OS, respectively), those younger than 65 years (FPRP ¼ 0.031 and 0.042 for LRFS and PFS, respectively), and those with stage III or IV disease (FPRP ¼ 0.007, 0.019, and 0.048 for LRFS, PFS, and OS, respectively). The omnibus chi-square test of the genotype frequency distributions.
c Calculated using study subjects to detect an OR of 2.00 with the common genotype used as the reference in FPRP level 0.2.
For ATG10 rs4703533, when the assumption of a prior probability was 0.25, the associations of clinical outcomes with the ATG10 rs4703533GG genotypes (a recessive genetic model) were still noteworthy for all subjects (FPRP ¼ 0.035, 0.039, and 0.154 for LRFS, PFS, and OS, respectively), those age 65 years or older (FPRP ¼ 0.194, 0.063, 0.047, and 0.139 for RP, LRFS, PFS, and OS, respectively), and a GVT less than 108 cm 3 (FPRP ¼ 0.030, 0.035, and 0.090 for LRFS, PFS, and OS, respectively) (Supplementary Table 8 ). For ATG12 rs1058600, when the assumption of a prior probability was 0.25, the associations of clinical outcomes with the ATG12 rs1058600TT genotype (a recessive genetic model) were still noteworthy for all subjects and subgroups (Supplementary Table 9 ).
Differential mRNA Expression of ATG16L2 and Functional Analysis of ATG16L2 rs10898880
We also evaluated differential mRNA expression levels of ATG16L2 in tumor tissues from 50 LUSCs, 57 LUADs, and paired adjacent normal tissues by using the data generated by The Cancer Genome Atlas. As shown in Figure 2A and B, the expression levels of ATG16L2 were significantly lower in LUSC and LUAD than that in the adjacent normal tissues (p ¼ 1.14 Â 10 -6 and 3.36 Â 10 -5 , respectively). To identify the putative functional role of ATG16L2 rs10898880, functional annotations from the ENCODE data indicate that rs10898880 is situated at a locus with transcription factor binding, DNase hypersensitivity, and histone modification patterns that are characterized as the promoters in several cell types, which present strong signals of active enhancer and promoter functions (Fig. 2C) . Moreover, the rs10898880 is within the ATG16L2 promoter region and is predicted to be located at transcription factor binding sites by the SNPinfo online tool. To provide biologically plausible support for the observed association and prediction, we evaluated the correlation between the rs10898880 SNP and ATG16L2 mRNA expression levels by genotype, using mRNA expression data of the blood cells from 338 European descendants by expression quantitative trait loci analysis with data from the Genotype-Tissue Expression project. The results showed that the rs10898880 variant C allele was associated with increased mRNA expression levels of ATG16L2 (p ¼ 1.4 Â 10 -10 ) (Fig. 2D) .
These data strongly suggest that the ATG16L2 rs10898880 C variant allele may modulate gene expression levels of ATG16L2.
Discussion
In the present study, we have investigated the associations of nine potentially functional SNPs in ATG2B, ATG10, ATG12, and ATG16L2 with severe RP, LRFS, PFS, and OS in 393 patients with NSCLC after definitive radiotherapy with or without chemotherapy. We found that the ATG16L2 rs10898880CC variant genotype and ATG10 rs4703533GG variant genotype contributed to a significantly better outcome but a greater risk of RP in patients with NSCLC; stratified analyses showed that the ATG16L2 rs10898880CC variant genotype was more evident in subgroups younger than 65 years and stage III or IV disease. Although multiple tests had been performed in the present study, the results of FPRP indicated that the associations of the potentially functional C variant of ATG16L2 rs10898880 with severe RP, LRFS, PFS, and OS were less likely to be false-positive. We also provided biological evidence that the mRNA expression levels of ATG16L2 were lower in lung cancer tissue than that in normal lung tissue and that the ATG16L2 rs10898880CC variant genotype was associated with higher mRNA expression levels of ATG16L2 than were AA and AC genotypes in the whole blood cells. These data imply that the ATG16L2 rs10898880 C variant may play a role in the severe RP and clinical outcomes of patients with NSCLC by modulating the mRNA expression levels of ATG16L2. Therefore, our results suggest that once these results have been validated by additional investigations, the ATG16L2 rs10898880 functional C variant may be a useful biomarker for predicting severe RP and clinical outcomes of patients with NSCLC after definitive radiotherapy.
Although dysfunctional study of the ATG genes has addressed the roles of autophagy in both cell death and survival, 42 few studies to date have explored the role of genetic variants of ATGs in severe RP and clinical outcomes of lung cancer. 8 We selected ATG2B because it is a newly discovered gene that participates in the autophagy pathways. 43 As an important player in autophagy, ATG2B is essential for autophagosome formation and necessary for closure of isolation membranes of autophagosomes. 44 The mutations in ATG2B have been shown to lead to the loss 1039 of the total 2078 amino acids, and loss-of-function mutations in ATG2B, which was overexpressed in primary hematopoietic cells from patients compared with in donor cells, have been identified in gastric and colorectal cancers. 17, 45 However, the role of genetic variants of ATG2B in cancer susceptibility is largely unknown.
In a cohort of 192 patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin, Buffen et al. demonstrated that the ATG2B rs3759601 SNP was correlated with progression and recurrence of bladder cancer after bacillus Calmette-Guérin intravesical instillation therapy. 30 In contrast, in another study of 238 patients with Paget disease of bone and 264 sex-matched controls, Usategui-Martín et al. found that genotype frequencies did not differ significantly between patients with Paget disease of bone and healthy subjects. 46 In the present study, we observed that ATG2B rs17784271 variant G allele was associated with a poor LRFS and PFS, but we did not find an association of the variant genotypes with risk of severe RP and OS in patients with NSCLC, suggesting that the ATGB2 rs17784271 variant G allele may play a role in the LRF and PFS of NSCLC after definitive radiotherapy.
ATG10 has been mapped to chromosome 5q14, which codes for an autophagic E2-like enzyme essential for the autophagosome formation. 47 A previous study reported that increased ATG10 expression was strongly associated with tumor invasion and metastasis, and as an oncogenic gene, ATG10 may be a potential prognostic maker for colorectal cancer. 32 In one study of 1064 case patients with breast cancer and 1073 cancer-free controls in a Chinese population, the authors found that genetic variants in ATG10 rs10514231 were associated with risk of breast cancer. 31 More recently, in another survival study of 1001 Chinese patients with NSCLC, Xie et al. observed that variant alleles of rs10514231 and rs1864182 were associated with a poor OS and that these variants were associated with the increased methylation levels of cg17942617. 8 The authors also observed that the elevated mRNA expression of ATG10 predicted a shorter survival. 8 In the present study, we did not observe a significant association between genetic variant in rs10514231 and RP or clinical outcomes of patients with NSCLC. However, we found that the ATG10 rs4703533 GG variant genotype contributed to a significantly increased risk of severe RP and a longer LRFS and PFS of patients with NSCLC. These findings need to be validated by other studies with large samples and indepth functional experiments, and ethnic background should be carefully considered in further studies.
ATG12 plays a critical role in autophagy. 15, 16 Recent studies have indicated that ATG12 transcript is commonly up-regulated in trastuzumab-unresponsive erb-b2 receptor tyrosine kinase 2-overexpressing breast cancer cells and that ATG12 silencing significantly reduced ATG12-shRNA/JIMT1 (breast cancer cell line) tumor growth induced by subcutaneous injection of trastuzumab in nude mice. 21 However, the role of ATG12 variants in risk and clinical outcomes of cancer is largely unknown. One previously published study assessed the association between the ATG12 rs26538 polymorphism and risk of breast cancer in 1064 case patients and 1073 controls in a Chinese population, but no significant association with cancer risk was found. 31 Other studies found that there was no significant association with survival and brain metastasis of NSCLC in Chinese patients. 8, 27 In the present study, we genotyped two functional SNPs of this gene, and similarly, we also did not find a significant association between ATG12 rs26538 SNP and RP or clinical outcome of white patients with NSCLC. However, our analysis of the ATG12 rs1058600 SNP showed that the variant T allele was associated with a better LRFS, PFS, and OS, suggesting that the ATG12 rs1058600 variant T allele may play a role in clinical outcomes of NSCLC after definitive radiotherapy. The functional rs1058600 T variant is located in the 3 0 UTR of the ATG12 primary transcript and in the predicted microRNA binding site (microRNA-181 and microRNA-494) (http://snpinfo.niehs.nih.gov/snpfunc.htm). It has been reported that microRNA-181 functions as a tumor suppressor or a tumor promotor by influencing expression of the target genes at the posttranscriptional level 48 and microRNA-494 expression was correlated with lung cancer progression in mice. 49 These may partly explain the underlying biological and molecular mechanisms for the observed associations, which need to be further investigated.
It is known that autophagy-related protein 16 like (including autophagy-related protein 16 like 1 and autophagy-related protein 16 like 2 [ATG16L2]) is an important regulator of autophagy and plays key roles in the autophagy pathway and tumorigenesis. 50 However, the exact molecular mechanism of ATG16L2 is still unclear. Previously, one study reported that the isoform autophagy-related protein 16 like 1 was essential for autophagy, whereas ATG16L2 did not seem to be important. 51 Later, another study of cell responses to cisplatin treatment used the ATG16L2 antibody to monitor expression of autophagy and cell death-related genes, 52 which showed that ATG16L2 levels were reduced in response to cisplatin, a possible biomarker or target for tumor cell resistance to the platinum-based drugs. 52 Recently, Atg16L2 mutants were found to have a more severe defect than Atg16L1 mutants in Caenorhabditis elegans. 53 A more recent study reported that ATG16L2 was a ubiquitously expressed homologue of ATG16L1 and the ATG16L2 interacts with ATG5 and codes for a protein related to autophagy and formation of autophagosome. 54 In one study of 54 patients with multiple sclerosis and 55 healthy controls in a Chinese population, Yin et al. found that ATG16L2 might play an important role in autophagy (specifically, in T cells) and served as a potential biomarker to predict clinical relapse of multiple sclerosis. 36 In another study of a genome-wide association scan of 1174 case patients with systemic lupus erythematosus and 4248 controls in a Korean population, the authors observed that ATG16L2 was involved in the association with systemic lupus erythematosus. 54 Similarly, in a Chinese population study of 363 case patients with Crohn's disease and 486 controls, the authors observed that mRNA expression levels of ATG16L2 were lower in the T cells of the patients than in those of the controls and that an increasing mRNA expression level of ATG16L2 in patients with the ATG16L2 rs11235604CC genotype were associated with a decreased risk of Crohn's disease. 37 However, the exact role of ATG16L2 in lung cancer development and progression remains unclear and needs to be further investigated. On the basis of the important role of ATG16L2 in the autophagy pathway, we observed associations of two potentially functional SNPs in ATG16L2 with severe RP and outcomes in 393 patients with NSCLC after definitive radiotherapy. Lower mRNA expression levels of ATG16L2 in the lung cancer tissues and higher mRNA expression levels of ATG16L2 correlated with the rs10898880CC variant genotype in blood cells were observed, whereas the rs10898880 variant CC genotype was associated with a better LRFS, PFS, and OS, suggesting that the functional genetic variant of ATG16L2 rs10898880 may play a role in clinical outcomes of patients with NSCLC by modulating the mRNA expression levels of ATG16L2.
According to the ENCODE project data from the University of California Santa Cruz, rs10898880 was associated with considerable levels of histone modification of H3K27 acetylation (H3K27Ac), monomethylation of lysine 4 (H3K4Me1), and trimethylation of lysine 4 of the H3 (H3K4Me3) histone protein enrichment, which may be associated with promoter function, and histone modifications may influence gene expression. 55 More interestingly, our results also showed that among patients with NSCLC, severe RP was more likely to occur in those carrying the rs10898880CC genotype than in those carrying the rs10898880 AA/AC genotypes. This finding is consistent with previous reports showing that overexpression of ATG16 inhibited autophagosome formation and resulted in tissue inflammatory response. 20, 25, 26 However, this hypothesis needs to be tested in future studies.
To the best of our knowledge, the present study is the first focusing only on associations of the potentially functional SNPs of ATGB2, ATG10, ATG12, and ATG16L2 with severe RP, LRFS, PFS, and OS in patients with NSCLC after definitive radiotherapy. However, there were some limitations in the present study. First, the present study included patients treated over a 10-year period, during which the standard of care in terms of both staging and treatment (especially the changes in chemotherapy dose and duration) may have changed, and information on these was not available and could not be controlled for in the multivariate analysis. Second, we were unable to explore the exact mechanisms by which the ATG SNPs influence severe RP and outcomes of patients with NSCLC, because we did not have the access to the target tissues. Third, we used the reported common functional SNPs, which may not include all representative SNPs in the entire gene. Some other rare functional SNPs, which could influence survival, may have been missed and need to be investigated in future larger studies. Fourth, genetic variants of AGT16L2 were suggested to predict the response to radiotherapy, which may be merely a prognostic biomarker for patients with NSCLC after definitive radiotherapy. Fifth, the impact of EGFR and ALK receptor tyrosine kinase gene (ALK) were not evaluated in the present study, because we did not have the mutation data of these genes, although our previous study had suggested that vascular endothelial growth factor gene (VEGF) mutation -460 C genotypes may be associated with a better survival of patients with NSCLC after chemoradiotherapy. 6 However, this should be further investigated in the future. Sixth, we did not find a suitable and accessible patient population for the validation of our results. Last, additional larger validation studies with multiethnic groups are needed to confirm our results, because our prognosis-predicting model was based on a North American patient population.
In conclusion, we found that potentially functional genetic variants of ATG16L2 predicted risk of RP and better LRFS, PFS, and OS in patients with NSCLC treated with definitive radiotherapy with or without chemotherapy. Whether the SNPs have an impact on the prognosis of NSCLC directly through alteration of autophagy or by other, possibly indirect mechanisms should be further investigated in the future. Once our results have been validated, patients who at a high risk for development of RP should receive a closer follow-up and should be considered for adjuvant therapy in the consideration of individualized treatment.
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